CALL US AT: (949) 396-0330

NEMUS Bioscience, Inc.

NEMUS Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids.

Meet Our Team


Cosmas N. Lykos , , Esq , , Co-Founder, Strategic Advisor, Chairman - Board of Directors

Cosmas Lykos co-founded Nemus in 2012 and has served as its Chairman of the Board of Directors since August 2014 as well as a strategic advisor since inception. After graduating with Honors from Duke University School of Law in 1993, Mr. Lykos began his career at Gibson Dunn & Crutcher, LLP, an international full-service law firm, as a corporate associate until 1998. From 1998 to 2004, Mr. Lykos served as Vice President of Business Affairs, General Counsel, Secretary and Chief Compliance Officer of RemedyTemp, Inc., a NASDAQ publicly-traded temporary staffing firm with over 250 directly-owned and franchised offices nationwide. From 2004 until 2008, Mr. Lykos served as Vice President of Business Development, Chief Legal Officer, Secretary and Chief Compliance Officer of Oakley, Inc., a NYSE publicly-traded sports and technical eyewear, apparel, accessories and retail company. In January of 2008, he became Co-owner and President of the Optical Shop International, a designer and distributor of licensed eyewear brands, including Chrome Hearts and Blinde, through two wholly-owned foreign subsidiaries with a direct and distributor sales network in over 60 countries around the world. Primary responsibilities included developing and implementing OSI’s vision and strategies and the management of its foreign subsidiaries, sales, legal, human resources, finance and administrative functions. In January 2011, Mr. Lykos negotiated and consummated the sale of OSI to its primary licensor, Chrome Hearts LLC. From January 2011 through present day, Mr. Lykos has been engaged to provide management and legal advisory services to Chrome Hearts Eyewear LLC and Chrome Hearts LLC. Mr. Lykos has extensive public and private company board of directors experience. As Chief Compliance and Legal Officer and Secretary of both Oakley, Inc. and RemedyTemp, Inc., Mr. Lykos attended all board of director meetings and board committee meetings. As an angel investor, Mr. Lykos has made minority investments in various private companies and has served on their Board of Directors including Dragon Alliance, LLC, a youth lifestyle action sports brand selling eyewear, goggles and apparel in over 40 countries, and, an internet e-commerce eyewear company, selling prescription frames and sunglasses direct to consumers.

Doug Ingram , , , Vice Chairman - Board of Directors

Mr. Ingram brings nearly 20 years of pharmaceutical leadership experience to the NEMUS board. As President of Allergan, Mr. Ingram reported directly to its CEO and led the company’s global commercial operations, with responsibility for the company’s broad portfolio of pharmaceutical, consumer and medical device products, including leading ophthalmology products. On March 17, 2015, Allergan was acquired by Actavis plc. With the acquisition, Mr. Ingram assumed the role of special advisor to the CEO of Actavis. During his tenure as President of Allergan, Mr. Ingram led a team that effected a major restructuring of the company, reducing expenses by over $500 million dollars while driving enhanced sales and earnings growth, all of which significantly improved the market capitalization of the company. Prior to his role as President, Mr. Ingram had served as Executive Vice President and President, Europe, Africa and Middle East (EAME) of Allergan. In this role, he was responsible for Allergan’s regional pharmaceutical and medical device operations, with a focus on strategic planning, sales and marketing, and general management. Prior to leading the EAME region, Mr. Ingram served as Executive Vice President and Chief Administrative Officer. During Mr. Ingram’s tenure in this role, at various times, he led Allergan’s Global Legal Affairs, Compliance, Internal Audit and Internal Controls, Human Resources, Regulatory Affairs and Safety, and Global Corporate Affairs and Public Relations departments. Mr. Ingram also served as Allergan’s Secretary and Chief Ethics Officer from July 2001 to July 2010. Prior to joining Allergan, Mr. Ingram was an attorney at Gibson, Dunn & Crutcher LLP from 1988 to 1996. Mr. Ingram received his Juris Doctorate from the University of Arizona in 1988, graduating summa cum laude and Order of the Coif.

Brian Murphy , , MD, MPH, MBA , , Member – Board of Directors, Chief Executive Officer and Chief Medical Officer

Dr. Murphy has more than 15 years experience in drug development and evaluation, both from the academic and industry perspective. He most recently served as the Chief Medical Officer of Eiger Biosciences. Previously, Dr. Murphy was Chief Medical Officer at Valeant Pharmaceuticals International (VRX) where his responsibilities also included oversight of Global Medical Affairs and Pharmacovigilance. Dr. Murphy also served as Medical Director, then Vice President of Marketing and Commercial Strategy of Hepatology for InterMune, Inc. (ITMN). Prior to InterMune, Dr. Murphy was Medical Director of North America for Antivirals/Interferons at Hoffmann-LaRoche. Prior to joining industry, Dr. Murphy was Assistant Professor of Medicine at New York Medical College and was Director of the Clinical Strategies Programs at St. Vincent's Hospital in New York City, the lead hospital of the Catholic Healthcare Network of New York. Dr. Murphy is board-certified in internal medicine and completed his residency in internal medicine at Tufts-New England Medical Center and served as Chief Medical Resident in the Boston University program. He went on to complete parallel fellowship tracts at Harvard Medical School, one in internal medicine/clinical epidemiology at the Massachusetts General Hospital and the other in medical ethics addressing issues of distributive justice and access to care. Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the Columbia University Graduate School of Business.

Tom George , , , Chairman - Audit Committee, Member - Board of Directors

Mr. George has over thirty years of experience in corporate finance and accounting, having served in a number of senior level positions with both public and private companies. Mr. George joined Deckers Brands as Chief Financial Officer in September 2009. Prior to Deckers, Mr. George was with Ophthonix, Inc. where he served as Chief Financial Officer since February 2005. Prior to Ophthonix, Mr. George spent more than seven years as Chief Financial Officer for publicly held Oakley, Inc., now a division of Luxottica Group S.p.A. (NYSE: LUX). Earlier in his career, Mr. George held positions at Loral Corporation, International Totalizator Systems, Remec Corporation and Coopers and Lybrand. Mr. George is a graduate of the University of Southern California.

Gerald W. Mclaughlin , , MBA , , Strategic Advisor, Member - Board of Directors

Gerald W. Mclaughlin is a seasoned business executive with proven success in the pharmaceutical, medical device and healthcare related industries. Gerald is currently the CEO of AgeneBio, a therapeutics development company targeting the Alzheimer’s space. Gerald has held multiple positions demonstrating leadership in shaping corporate strategy, raising capital, commercial operations, product development, launches and business development. Gerald developed his skillsets working for Merck & Co. Inc. as an Associate Director of Marketing (Anti-Infectives) where he was the lead in developing and implementing global brand strategies for 3 new drug launches (Vioxx, Primaxin, Invanz). The Vioxx launch was archived as the most successful launch in Merck history with US sales exceeding $1 B in the first year. Gerald also acted as a Senior Director of Strategic Marketing for Endo Pharmaceuticals where he established a strategic roadmap for the organization and performed commercial assessments for new opportunities encompassing all aspects of pan management including neuropathic pain, post-operative and breakthrough pain. Most recently, Gerald acted as the Senior Vice President and Chief Commercial Officer for NuPathe Inc. where he helped provide strategic direction and commercial operations from the ground level to its acquisition in Q1 2014 by Teva Pharmaceuticals Ltd. for a total deal value of $270 MM. Gerald received his BA in Economics from Dickinson College and his MBA from Villanova University.

    Management Team

    Meet our team of industry veterans working together to ensure Nemus Bioscience Inc. remains a leading biopharmaceutical company.

    Meet Our Management Team

    Board of Directors

    Meet our Board of Directors, the team responsible for review and oversight of Nemus strategy and management.

    Meet Our Board of Directors